abstract
virus
obligatori
intracellular
parasit
whose
replic
depend
pathway
function
host
cell
consequ
difficult
defin
virusspecif
function
suitabl
target
antiinfect
therapi
howev
signific
progress
made
past
year
toward
develop
effect
specif
antivir
particular
human
immunodefici
viru
hepat
c
viru
hepat
b
viru
caus
chronic
infect
affect
million
individu
worldwid
major
focu
antivir
research
initi
antivir
mainli
direct
virusspecif
enzym
recent
drug
inhibit
step
viru
entri
releas
develop
ration
approach
toward
drug
develop
base
inform
structur
function
viral
protein
molecular
mechan
virushost
interact
becom
increasingli
success
novel
strategi
current
explor
basic
research
preclin
studi
includ
approach
target
host
factor
import
viru
replic
exploit
innat
immun
respons
system
well
use
gene
silenc
strategi
aim
interf
viral
gene
express
today
number
effect
virostat
target
variou
viral
replic
step
approv
treatment
import
viral
diseas
howev
use
drug
limit
rapid
develop
antivir
resist
repres
central
problem
current
antivir
therapi
virus
obligatori
intracellular
parasit
whose
replic
depend
function
host
cell
defin
featur
number
consequ
develop
applic
antivir
drug
intracellular
replic
appropri
cellular
pathway
purpos
pathogen
make
difficult
defin
virusspecif
target
therapeut
intervent
inhibit
strategi
highli
specif
prevent
cell
toxic
furthermor
viral
depend
suitabl
host
cell
fact
pathogen
small
visibl
light
microscopi
complex
system
requir
propag
virus
laboratori
detect
viru
replic
test
potenti
inhibitor
tissu
cultur
molecular
biolog
establish
routin
method
develop
antivir
therapi
depend
fortuit
discoveri
exampl
observ
thiosemicarbazon
origin
employ
treat
tuberculosi
could
also
inhibit
vaccinia
viru
replic
hamr
et
al
base
find
thiosemicarbazon
deriv
marboran
activ
relat
smallpox
viru
develop
use
first
virostat
treat
human
viru
infect
bauer
et
al
review
see
bauer
past
year
medium
high
throughput
random
screen
antivir
compound
structurebas
antivir
drug
design
becom
possibl
compar
simpl
composit
virus
valid
target
vitro
screen
often
rather
straightforward
procedur
preclin
clinic
test
differ
appli
case
drug
field
antivir
research
undergon
remark
progress
past
three
decad
number
potent
antivir
drug
sever
differ
class
activ
import
viral
pathogen
current
approv
see
tabl
howev
select
antivir
avail
clinic
use
still
rel
limit
compar
antibacteri
drug
new
drug
urgent
requir
chapter
outlin
principl
challeng
antivir
therapi
present
brief
overview
current
use
antivir
drug
futur
prospect
topic
touch
follow
section
discuss
detail
follow
chapter
compar
bacteria
eukaryot
parasit
virus
simpl
pathogen
describ
piec
bad
news
wrap
protein
medawar
medawar
genom
encas
protect
shell
compos
protein
case
envelop
virus
lipid
contrast
mammalian
cell
bacteri
fungal
parasit
pathogen
virus
group
share
type
genom
principl
replic
viral
genom
consist
singleor
doublestrand
dna
rna
virus
classifi
accord
type
genom
genom
replic
strategi
use
fig
furthermor
nake
ie
contain
protein
shell
envelop
lipid
membran
surround
protein
shell
deriv
host
cell
membran
import
human
pathogen
found
mani
differ
viru
famili
implic
antivir
intervent
doublestrand
dna
virus
larg
use
cellular
pathway
genom
replic
rna
virus
virus
replic
cytoplasm
provid
enzym
mediat
virusspecif
replic
strategi
enzym
repres
target
specif
inhibit
see
sect
herein
contrari
viral
rna
polymeras
gener
errorpron
mammalian
dna
polymeras
viral
replic
mechan
favor
genet
recombin
therebi
promot
rapid
adapt
immun
evas
antivir
resist
develop
see
sect
herein
although
detail
replic
mechan
differ
significantli
virus
virus
undergo
gener
replic
step
outlin
fig
fig
classif
virus
genom
replic
strategi
accord
baltimor
baltimor
exampl
import
human
pathogen
fall
respect
class
list
black
dna
gray
rna
arrow
right
strand
polar
ie
correspond
mrna
arrow
left
strand
asterisk
envelop
virus
virion
defin
infecti
viral
particl
attach
host
cell
recognit
appropri
target
cell
bind
mediat
viral
surfac
envelop
protein
interact
one
cellular
membran
protein
andor
attach
factor
plasma
membran
eg
heparan
sulfat
proteoglycan
sialic
acid
subsequ
virus
enter
cell
either
uptak
varieti
endocyt
pathway
directli
plasma
membran
envelop
virus
enter
viral
surfac
protein
mediat
fusion
viral
lipid
envelop
plasma
membran
often
phdepend
manner
endosom
membran
releas
viral
core
cytoplasm
nake
virus
appli
fusion
mechan
devis
strategi
cross
lipid
bilay
follow
uncoat
step
releas
viral
genom
protect
proteinac
shell
current
poorli
understood
virus
subsequ
replic
viral
genom
occur
differ
mechan
differ
virus
depend
type
genom
site
viru
replic
within
cell
transcript
posttranscript
modif
viral
mrna
translat
case
carri
cellular
machineri
may
modifi
virusencod
factor
newli
gener
viral
protein
genom
transport
cellular
pathway
specif
assembl
site
within
host
cell
eg
plasma
membran
intracellular
viru
factori
form
progeni
particl
releas
particl
occur
cell
lysi
observ
nake
virus
case
envelop
virus
bud
cellular
membran
lead
acquisit
lipid
envelop
case
gener
infecti
progeni
requir
subsequ
step
term
matur
involv
conform
rearrang
virion
architectur
often
trigger
proteolyt
process
viral
structur
protein
chang
environ
eg
acid
ph
principl
step
consid
target
antivir
intervent
thu
inhibit
viru
replic
could
either
accomplish
interf
specif
virusreceptor
interact
plasma
membran
viral
entri
process
block
viral
enzym
involv
genom
replic
proteolyt
matur
affect
viru
releas
recent
inhibit
viral
gene
express
replic
use
antisenserna
smallinterf
si
rna
mediat
silenc
demonstr
experiment
set
yet
yield
new
therapeut
option
target
step
reli
mostli
cellular
factor
transcript
translat
transport
viral
compon
conceptu
difficult
cellular
factor
machineri
could
present
attract
target
due
genet
stabil
inhibit
without
major
toxic
effect
specif
interfer
host
cell
factor
cellular
machineri
usurp
virus
may
achiev
provid
detail
knowledg
particular
viru
use
pathway
viral
cellular
factor
involv
avail
addit
direct
interfer
viral
function
factor
antivir
treatment
also
involv
immunomodulatori
strategi
see
sect
herein
sever
principl
requir
differ
level
knowledg
methodolog
appli
identif
antivir
substanc
see
chapter
schinazi
et
al
volum
first
compound
alreadi
use
therapeut
known
inhibit
anoth
pathogen
could
fortuit
discov
inhibit
replic
pathogen
viru
principl
exemplifi
thiosemicarbazon
deriv
activ
poxvirus
mention
earlier
likewis
nucleosid
analog
use
inhibitor
viral
polymeras
see
later
relat
antiprolif
drug
target
cellular
polymeras
highli
replic
tumor
cell
howev
fortuit
discoveri
obvious
repres
ideal
strategi
develop
specif
effect
drug
thiosemicarbazon
exampl
found
induc
sever
advers
effect
combin
limit
efficaci
systemat
approach
inhibitori
compound
identifi
random
screen
purpos
number
compound
librari
compil
accord
differ
principl
eg
natur
compound
small
molecul
peptid
druglik
molecul
ligandbas
pharmacophor
avail
commerci
noncommerci
sourc
beyond
systemat
search
antivir
yet
tap
full
potenti
natur
substanc
mixtur
use
tradit
medicin
eg
herbal
extract
random
test
inhibit
replic
given
viru
tissu
cultur
rather
unbias
toward
specif
inhibitori
mechan
yield
preselect
compound
display
signific
cytotox
taken
cell
howev
although
tissu
cultur
mani
type
mammalian
cell
becom
routin
method
screen
set
rel
expens
time
consum
easili
autom
furthermor
virus
easili
propag
tissu
cultur
case
import
human
pathogen
hepat
c
viru
hcv
hepat
b
viru
hbv
signific
progress
toward
routin
tissu
cultur
system
accomplish
within
past
year
gripon
et
al
wakita
et
al
recent
system
develop
allow
medium
high
throughput
screen
approach
altern
system
highthroughput
random
screen
antivir
set
defin
specif
viral
target
establish
vitro
assay
appropri
measur
function
viral
factor
presenc
absenc
inhibitor
virusencod
enzym
particularli
well
suit
target
approach
case
one
build
longstand
expertis
similar
approach
area
drug
develop
exampl
metabol
diseas
howev
vitro
system
mimick
nonenzym
mediat
step
viru
replic
exampl
viru
assembl
proteinprotein
interact
viral
cellular
factor
also
develop
type
random
screen
compound
librari
like
identifi
drug
suit
treatment
first
round
rather
yield
lead
compound
valid
altern
assay
procedur
subsequ
improv
potenc
pharmacolog
properti
iter
cycl
chemic
modif
test
fundament
differ
approach
procedur
ration
drug
design
start
detail
inform
molecular
structur
function
specif
viral
target
substanc
expect
bind
target
interfer
function
identifi
computeraid
design
subsequ
synthes
test
inhibitori
action
suitabl
assay
procedur
test
inhibitori
potenti
silico
defin
lead
compound
develop
properti
substanc
improv
iter
procedur
noteworthi
rather
limit
current
arsen
antivir
alreadi
compris
sever
highli
effect
drug
result
structur
base
drug
design
approv
inhibitor
human
immunodefici
viru
hiv
proteas
well
influenza
viru
neuraminidas
develop
ration
design
highlight
valid
feasibl
approach
identif
valid
target
develop
appropri
assay
identif
lead
compound
requir
effort
academ
research
well
pharmaceut
industri
optim
extens
preclin
clinic
test
candid
drug
beyond
scope
academ
institut
accomplish
pharmaceut
industri
consid
antiinfect
therapi
one
first
think
cur
treatment
aim
rapid
elimin
pathogen
human
organ
concept
hold
true
treatment
bacteri
infect
antibiot
howev
case
antivir
therapi
cur
treatment
except
rather
rule
mani
human
viru
infect
character
acut
selflimit
cours
case
peak
viru
replic
therapeut
intervent
would
effect
often
preced
appear
clinic
symptom
viru
specif
antibodi
detect
routin
diagnost
assay
antivir
therapi
later
time
point
symptom
immunolog
marker
appear
limit
clinic
benefit
acut
infect
still
entail
risk
side
effect
import
acut
viru
infect
antivir
treatment
avail
influenza
influenza
viru
caus
sever
even
lifethreaten
acut
diseas
untreat
patient
associ
devast
pandem
reason
signific
effort
undertaken
develop
effect
antiinfluenza
viru
drug
four
substanc
act
influenza
viru
belong
two
differ
drug
class
amantadinerimantadin
neuraminidas
inhibitor
current
approv
see
chapter
von
itzstein
thomson
volum
acut
viral
infect
therapi
mostli
involv
symptomat
treatment
case
immunomodulatori
rel
unspecif
therapi
use
interferon
ifn
ribavirin
see
later
treatment
antivir
drug
gener
relev
case
persist
chronic
viral
infect
current
avail
antivir
therapi
direct
diseas
treatment
case
obvious
also
aim
erad
viral
pathogen
host
current
achiev
mani
instanc
case
therapi
aim
lower
viral
load
allevi
prevent
clinic
manifest
longterm
consequ
chronic
infect
eg
liver
cirrhosi
hepatocellular
carcinoma
associ
chronic
hbv
hcv
infect
prevent
transmiss
pathogen
case
herp
virus
caus
persist
infect
antivir
drug
use
allevi
symptom
primari
infect
treat
recurr
infect
aim
forc
viru
back
latent
state
chronic
infect
hbv
hcv
requir
prolong
virostat
treatment
suppress
viral
load
mani
case
eventu
elimin
infect
hiv
current
believ
erad
viru
organ
requir
decad
antivir
therapi
might
possibl
case
indic
initi
therapi
base
clinic
paramet
therapi
aim
sustain
suppress
plasma
viral
load
improv
patient
condit
longterm
treatment
chronic
infect
fraught
problem
regard
advers
effect
drug
patient
complianc
therapi
cost
importantli
resist
develop
see
sect
herein
combin
therapi
may
requir
ensur
effici
reduct
viral
load
prevent
emerg
resist
variant
see
chapter
hofmann
zeuzem
volum
case
chronic
hepat
c
combin
therapi
ribavirin
pegyl
ie
coval
coupl
polyethylen
glycol
led
signific
improv
success
rate
compar
monotherapi
see
chapter
chevaliez
pawlotski
volum
mann
et
al
fri
et
al
case
current
standard
combin
therapi
highli
activ
antiretrovir
therapi
haart
use
least
three
drug
one
inhibitor
class
antihiv
monotherapi
accept
specif
set
eg
singl
dose
treatment
prevent
mothertochildtransmiss
rapid
resist
develop
see
sect
reason
antivir
treatment
chronic
diseas
requir
expert
knowledg
monitor
therapeut
effect
care
adjust
therapi
regimen
anoth
fundament
differ
virus
pathogen
affect
develop
antiinfect
concern
fact
virus
strongli
reli
host
cell
pathway
mani
replic
step
thu
present
mani
pathogenspecif
target
pharmaceut
intervent
structur
metabol
featur
common
mani
virus
fundament
differ
featur
mammalian
cell
compar
exampl
bacteri
cell
wall
ribosom
distinct
metabol
pathway
parasit
pathogen
therefor
broadspectrum
antivir
difficult
conceiv
select
effect
drug
antivir
treatment
usual
requir
ident
pathogen
precis
determin
diagnost
procedur
current
genomewid
screen
approach
probe
exampl
relev
kinas
human
genom
replic
specif
virus
see
sect
herein
may
eventu
defin
common
requir
larger
group
virus
thu
pave
way
broader
act
antivir
target
host
cell
factor
accordingli
antivir
drug
avail
limit
number
virus
contrast
larg
select
antibacteri
compound
spite
difficulti
outlin
earlier
amaz
progress
made
antivir
therapi
past
year
although
hiv
discov
year
ago
drug
target
three
differ
viral
replic
step
approv
treat
hiv
infect
number
virostat
effect
hepat
b
viru
herp
virus
also
constantli
grow
great
effort
basic
research
pharmaceut
compani
last
decad
similar
success
expect
case
hepat
c
indic
effect
drug
probabl
develop
pathogen
viru
provid
comprehens
dedic
effort
academ
research
industri
undertaken
may
easili
achiev
case
viru
diseas
preval
develop
world
concert
effort
includ
intern
organ
privat
donor
essenti
obtain
drug
virus
mostli
affect
poorer
countri
view
fact
mani
viral
diseas
great
impact
public
health
today
arisen
discov
past
three
decad
assum
import
new
viral
pathogen
continu
emerg
requir
novel
antivir
compound
persist
case
may
possibl
build
previou
accomplish
develop
drug
novel
pathogen
exampl
week
identif
previous
unknown
coronaviru
etiolog
agent
sever
acut
respiratori
syndrom
sar
structur
model
viral
proteas
potenti
target
inhibit
construct
homolog
model
base
structur
relat
coronaviru
proteas
anand
et
al
howev
even
fortun
case
optim
preclin
clinic
test
activ
virostat
still
requir
sever
year
develop
specif
inhibit
enzym
either
substrat
analog
alloster
compound
concept
wide
use
pharmacolog
thu
inhibit
pathogen
encod
enzym
principl
repres
straightforward
strategi
build
avail
knowledg
techniqu
case
viral
pathogen
use
approach
restrict
fact
viru
replic
strongli
reli
host
cell
function
viral
genom
often
encod
limit
set
enzym
howev
mani
virus
encod
nucleic
acid
polymeras
genom
replic
fundament
differ
mammalian
cell
togeth
fact
polymeras
gener
well
character
class
enzym
made
viral
replic
enzym
earli
target
direct
antivir
intervent
classic
polymeras
inhibitor
belong
class
nucleosid
analog
term
chain
termin
see
chapter
neyt
declerq
volum
upon
modif
triphosph
within
cell
compound
resembl
natur
polymeras
substrat
dntp
incorpor
grow
nucleic
acid
chain
contrast
natur
substrat
lack
oh
group
requir
addit
subsequ
nucleotid
mani
viral
polymeras
rna
polymeras
revers
transcriptas
rt
lack
proofread
function
prevent
remov
incorpor
inhibitor
case
incorpor
singl
chain
termin
molecul
per
viral
genom
copi
lead
function
inactiv
genom
molecul
make
chain
termin
highli
effect
strategi
antivir
drug
belong
class
current
avail
herp
virus
eg
acyclovir
hiv
nucleosid
rt
inhibitor
nrti
hbv
eg
lamivudin
one
drawback
chain
termin
approach
activ
site
polymeras
target
substrat
analog
display
rel
high
degre
structur
conserv
enzym
differ
origin
thu
unwant
interfer
inhibitor
host
cell
polymeras
lead
side
effect
patient
treat
drug
eleg
way
circumv
problem
honour
nobel
prize
physiolog
medicin
gertrud
b
elion
discov
case
acyclovir
potent
inhibitor
replic
herp
virus
acyl
nucleosid
analog
poor
substrat
cellular
kinas
effici
phosphoryl
thymidin
kinas
herp
simplex
viru
hsv
monophosph
form
convert
triphosph
cellular
enzym
thu
activ
form
inhibitor
enrich
specif
infect
cell
mechan
reduc
advers
effect
drug
elion
et
al
acyclovir
display
minor
efficaci
herp
viru
cytomegaloviru
cmv
lack
thymidin
kinas
howev
relat
compound
ganciclovir
substrat
protein
kinas
cmv
use
accord
principl
acyclovir
ganciclovir
effect
virus
encod
kinas
capabl
mediat
initi
monophosphoryl
step
howev
acycl
nucleotid
analog
acycl
nucleosid
phosphon
develop
carri
one
phosphon
moieti
requir
two
subsequ
phosphoryl
step
de
clercq
et
al
independ
virusencod
kinas
display
broader
spectrum
efficaci
class
compris
import
drug
hiv
tenofovir
hbv
adefovir
tenofovir
well
cidofovir
approv
use
cmv
retin
also
display
except
broad
efficaci
profil
mani
herpesvirus
adenoviru
poxvirus
papillomavirus
de
clercq
holi
substanc
target
activ
site
display
inhibit
alloster
mechan
associ
lower
risk
unwant
interfer
relat
cellular
enzym
alloster
inhibit
viral
polymeras
employ
case
nonnucleosid
rt
inhibitor
nnrti
see
chapter
zimmermann
et
al
volum
bind
outsid
rt
activ
site
act
block
conform
chang
enzym
essenti
catalysi
potenti
disadvantag
target
region
distant
activ
site
may
subject
lower
select
pressur
sequenc
conserv
activ
site
lower
threshold
escap
viru
mutat
second
biochem
well
character
class
enzym
frequent
found
virus
mani
differ
famili
proteas
pr
see
chapter
anderson
et
al
volum
limit
code
capac
virus
often
reli
product
polyprotein
need
proteolyt
process
function
subunit
often
carri
virusencod
proteas
belong
mechanist
class
known
cellular
counterpart
eg
thiolor
aspart
proteas
exhibit
structur
differ
activ
site
substratebind
pocket
proteas
inhibitor
current
clinic
use
hiv
substrat
analog
contain
uncleav
mimick
peptid
bond
flank
structur
element
resembl
specif
featur
cognat
cleavag
site
inhibitor
pr
hcv
eg
telaprevir
enter
stage
clinic
trial
inhibitor
pr
virus
exampl
sar
coronaviru
review
lai
et
al
west
nile
viru
dengu
viru
pox
viru
herp
virus
current
explor
laboratori
set
viral
integras
enzym
specif
retrovirus
polymeras
proteas
close
relat
counterpart
human
cell
mediat
coval
integr
viral
genet
inform
proviru
genom
host
cell
seri
concert
dna
cleavag
join
reaction
although
hiv
consid
attract
target
inhibit
mani
year
initi
studi
hinder
difficulti
faith
mimick
topolog
complex
reaction
vitro
system
signific
effort
research
develop
obstacl
overcom
sever
potent
inhibitor
hiv
identifi
see
chapter
zimmermann
et
al
volum
clinic
studi
yield
highli
promis
result
substanc
first
hiv
inhibitor
raltegravir
recent
approv
clinic
use
anoth
import
specif
enzymat
target
neuraminidas
found
envelop
influenza
virus
see
chapter
von
itzstein
thomson
volum
neuraminidas
function
essenti
viru
releas
influenza
virion
attach
host
cell
via
interact
viral
surfac
protein
hemagglutinin
sialic
acid
residu
cell
surfac
interact
facilit
cell
entri
imped
passag
incom
viru
respiratori
tract
keep
newli
form
virion
attach
produc
cell
remov
sialic
acid
cell
surfac
viral
neuraminidas
releas
viru
progeni
enabl
infect
new
host
cell
base
detail
inform
structur
enzym
interact
natur
substrat
transit
state
analog
sialic
acid
bind
high
affin
activ
site
neuraminidas
design
bossartwhitak
et
al
two
compound
deriv
approach
oseltamivir
zanamivir
approv
clinic
use
inhibitor
respiratori
virus
eg
parainfluenza
viru
may
develop
accord
principl
futur
alymova
et
al
like
viral
proteas
inhibitor
neuraminidas
inhibitor
among
still
rare
exampl
success
structurebas
ration
drug
design
theoret
basi
prevent
viral
pathogen
enter
host
cell
see
chapter
melbi
westbi
volum
repres
ideal
antivir
strategi
furthermor
develop
strategi
block
viral
entri
build
consider
amount
knowledg
viral
entri
protein
entri
mechan
review
see
sieczkarski
whittak
kielian
rey
surprisingli
though
inhibitor
act
earli
stage
viru
replic
found
current
avail
antivir
arsen
cours
immun
lead
develop
neutral
antibodi
effect
prevent
viral
entri
thu
infect
use
therapeut
approach
would
slow
combat
acut
infect
appear
difficult
chronic
viral
infect
viru
gener
replic
presenc
compet
host
immun
answer
oldest
exampl
chemic
target
viral
entri
amantadin
develop
random
screen
approach
approxim
year
ago
clinic
use
sinc
mechan
action
unravel
act
block
ion
channel
envelop
influenza
virus
turn
inhibit
conform
chang
passag
viru
acid
environ
endosom
therebi
prevent
releas
viral
core
cytoplasm
unfortun
rapid
widespread
resist
develop
sever
limit
use
drug
today
neuraminidas
inhibitor
see
sect
preferenti
recommend
hiv
enter
endocyt
pathway
deliv
genom
cell
fusion
viral
envelop
plasma
membran
fusion
mediat
viral
envelop
protein
insert
host
cell
membran
subsequ
conform
switch
two
protein
helic
form
coiledcoil
interact
draw
viral
cellular
membran
close
proxim
peptid
enfuvirtid
mimick
one
helic
bind
cognat
bind
site
therebi
block
conform
chang
enfuvirtid
approv
exampl
membran
fusion
inhibitor
drug
repres
fourth
class
antivir
hiv
recent
natur
peptid
virip
inhibit
hiv
fusion
differ
mechan
isol
human
blood
et
al
virip
block
coiledcoil
format
within
interact
fusion
peptid
region
prevent
contact
host
cell
membran
given
promis
preclin
data
peptid
may
readi
enter
clinic
trial
within
next
year
final
compound
inhibit
uncoat
nonenvelop
picornavirus
rhinovirus
enterovirus
develop
pleconaril
design
fit
hydrophob
canyon
capsid
protein
picornavirus
bind
drug
stabil
viral
capsid
prevent
releas
viral
genom
host
cell
pleconaril
shown
potent
inhibit
human
pathogen
rhinovirus
coxsackievirus
enterovirus
although
drug
shorten
clinic
cours
common
cold
approv
therapi
mild
diseas
requir
rigor
riskbenefit
assess
pleconaril
current
clinic
develop
use
enterovir
mening
differ
approach
target
virion
structur
molecul
interf
capsid
assembl
matur
viral
capsid
shell
assembl
either
singl
limit
number
differ
capsid
protein
mani
case
arrang
strictli
defin
symmetr
architectur
least
array
local
order
integr
capsid
depend
multipl
often
rather
weak
interact
monom
sinc
capsid
architectur
integr
may
disturb
interf
one
interact
site
within
shell
sinc
interfac
viral
capsom
like
viru
specif
capsid
assembl
repres
attract
target
antivir
therapi
howev
viru
assembl
inhibitor
identifi
date
mainli
due
insuffici
structur
inform
lack
suitabl
assay
system
random
screen
approach
nonnucleosid
inhibitor
hbv
replic
yield
subsequ
found
bind
specif
hbv
core
protein
perturb
viral
capsid
format
architectur
dere
et
al
bourn
et
al
case
peptid
inhibit
capsid
assembl
vitro
bind
specif
site
capsid
protein
describ
sticht
et
al
cell
permeabl
variant
peptid
shown
display
antivir
activ
tissu
cultur
zhang
et
al
format
viru
particl
also
subsequ
step
morpholog
rearrang
within
structurecapsid
matur
disturb
small
molecul
principl
exemplifi
betulin
acid
deriv
bevirimat
inhibit
matur
particl
li
et
al
review
see
allaway
contrast
hiv
pr
inhibitor
block
function
enzym
mediat
requir
proteolysi
structur
polyprotein
gag
bevirimat
affect
specif
one
sever
pr
cleavag
site
within
substrat
therebi
prevent
essenti
process
step
capsid
condens
virion
interrupt
process
matur
remain
noninfecti
compound
repres
prototyp
novel
class
hiv
inhibitor
current
clinic
develop
outlin
earlier
antivir
therapi
far
direct
viral
factor
ideal
case
complet
distinct
cellular
protein
function
virusspecif
approach
come
cost
howev
gener
high
replic
rate
mutat
frequenc
virus
result
high
rate
resist
develop
see
sect
herein
altern
cellular
factor
essenti
viral
replic
could
target
would
expect
mutat
antivir
drug
pressur
approach
much
difficult
realiz
target
virusspecif
function
drug
fall
class
yet
avail
select
appropri
cellular
target
requir
detail
inform
intric
network
virushost
interact
inform
best
rudimentari
viral
system
recent
target
knockdown
singl
cellular
gene
short
interf
rna
sirna
made
possibl
set
genom
wide
sirna
screen
allow
probe
requir
cellular
protein
viru
replic
mediumto
highthroughput
screen
advent
method
expect
mani
new
cellular
target
discov
near
futur
screen
focuss
cellular
kinas
import
viru
replic
yield
first
result
pelkman
et
al
damm
pelkman
recent
genom
wide
sirna
screen
identifi
potenti
cellular
interact
partner
hiv
brass
et
al
approach
like
identifi
factor
requir
specif
viru
well
factor
use
group
virus
therefor
might
futur
provid
basi
develop
broadspectrum
antivir
target
identifi
second
obstacl
inhibit
highli
specif
molecular
term
interfer
normal
function
respect
protein
reason
cellular
viru
receptor
conceptu
promis
candid
furthermor
sinc
virusreceptor
interact
occur
cell
surfac
inhibitor
block
interact
membran
permeabl
mani
pathogen
virus
receptor
requir
entri
identifi
mani
case
inform
molecular
interact
cognat
viral
protein
avail
favor
exampl
repres
human
transmembran
protein
play
role
coreceptor
delet
gene
render
protein
nonfunct
occur
natur
signific
number
individu
approxim
caucasian
popul
homozyg
without
appar
pathogen
consequ
thu
appear
function
dispens
although
independ
hiv
entri
possibl
block
interact
suffici
sever
affect
viru
replic
inhibitor
class
review
see
ray
dom
clinic
develop
antagonist
maraviroc
celsentri
selzentri
first
repres
new
class
antivir
drug
approv
addit
antagonist
altern
coreceptor
well
hiv
receptor
develop
similar
concept
also
explor
case
virus
exampl
peptid
correspond
myristoyl
nterminu
larg
envelop
protein
hbv
shown
block
hbv
replic
tissu
cultur
gripon
et
al
furthermor
hbv
infect
could
prevent
subcutan
applic
peptid
mice
harbor
transplant
hbvsuscept
hepatocyt
petersen
et
al
interact
viru
host
cell
often
result
activ
cellular
signal
pathway
virusinduc
signal
cascad
may
serv
mediat
antivir
respons
host
virus
also
exploit
pathway
enhanc
viral
replic
case
cellular
signal
molecul
potenti
target
antivir
intervent
influenza
viru
report
viru
replic
tissu
cultur
impair
inhibit
rafmekerk
kinas
pathway
appear
feasibl
target
pathway
without
detriment
effect
host
review
see
ludwig
realiz
approach
might
potenti
target
one
viru
famili
virus
make
extens
use
cellular
transcript
translat
machineri
virusspecif
inhibit
essenti
pathway
conceptu
difficult
one
exampl
may
ribonucleosid
deriv
ribavirin
snell
identifi
screen
search
broad
act
antivir
although
drug
character
rel
low
clinic
efficaci
high
probabl
side
effect
use
sever
infect
respiratori
syncyti
viru
proven
particularli
valuabl
combin
therapi
chronic
hepat
c
assum
antivir
activ
least
part
due
inhibit
cellular
rna
cap
machineri
also
usurp
mani
virus
modifi
rna
howev
sever
mode
action
immunomodul
inhibit
viral
rna
polymeras
incorpor
viral
nucleic
acid
lead
hypermut
lower
cellular
gtp
level
also
discuss
inhibit
complex
virushost
interact
exampl
promot
envelop
viru
bud
cellular
escrt
machineri
pornillo
et
al
bieniasz
intracellular
transport
viral
compon
via
cellular
pathway
discuss
promis
strategi
li
wild
howev
knowledg
virus
use
cellular
pathway
machineri
may
differ
normal
cellular
function
element
still
limit
thu
difficult
defin
compound
specif
interf
viruscel
interact
without
affect
essenti
cellular
pathway
complementari
approach
inhibit
cellular
factor
facilit
viru
replic
would
stimul
enhanc
cellular
factor
restrict
viru
replic
concept
intracellular
restrict
retrovir
infect
exist
natur
occur
speci
cell
type
specif
inhibitor
viru
replic
propos
sever
decad
ago
lilli
steev
lilli
respect
cellular
factor
mode
action
unclear
recent
studi
sever
lab
identifi
differ
cellular
restrict
factor
tripartit
motif
trim
review
nisol
et
al
luban
apobec
review
harri
et
al
protein
famili
inhibit
replic
hiv
retrovirus
certain
host
cell
result
greatli
advanc
understand
mechan
antivir
restrict
deeper
insight
system
requir
antivir
therapi
base
yet
identifi
intrins
restrict
factor
deriv
interact
virus
human
immun
system
repres
level
even
higher
complex
interact
virus
intracellular
network
mutual
adapt
virus
natur
host
organ
evolv
strategi
control
viru
infect
similarli
virus
develop
strategi
counteract
evad
defenc
mechan
review
see
seth
et
al
hengel
et
al
stimul
immun
system
administr
ifn
employ
rel
unspecif
therapi
differ
viru
infect
see
chapter
chevali
pawlotski
volum
addit
immunomodulatori
action
ifn
may
also
exert
direct
antivir
effect
outlin
earlier
pegyl
central
element
current
recommend
treatment
chronic
hepat
c
review
see
hoofnagl
seeff
pegyl
also
use
therapi
chronic
hepat
b
particular
adult
patient
sar
outbreak
treatment
patient
ifn
attempt
unclear
whether
result
clinic
benefit
stockman
et
al
also
envis
compound
specif
disturb
intric
relationship
given
viru
human
immun
system
could
employ
tip
balanc
favor
host
innat
immun
respons
repres
front
line
defens
organ
viral
pathogen
involv
recognit
virusspecif
structur
exampl
dsrna
uncap
rna
cellular
receptor
tolllik
receptor
retino
acid
induc
gene
rigi
melanoma
differentiationassoci
gene
result
trigger
signal
cascad
ultim
lead
releas
type
ifn
upregul
innat
immun
respons
could
enabl
organ
control
infect
immunomodulatori
cell
growth
promot
antivir
effect
ifn
analog
effect
could
accomplish
opposit
manner
suppress
virusspecif
mechan
evolv
antagon
cellular
pathway
recent
found
hcv
encod
pr
specif
cleav
inactiv
cellular
protein
cardif
mav
part
rigi
signal
cascad
innat
immun
system
meylan
et
al
johnson
gale
thu
inhibitor
hcv
pr
would
affect
essenti
process
viral
polyprotein
also
support
immun
defens
host
fend
viral
attack
innat
immun
system
foy
et
al
import
mechan
host
defenc
elimin
virusinfect
cell
apoptosi
evad
destruct
pathway
virus
express
factor
exert
antiapoptot
effect
within
infect
cell
eg
hengel
et
al
taylor
et
al
particular
herp
virus
develop
numer
strategi
antiapoptosi
often
employ
one
strategi
immun
evas
sinc
prevent
apoptosi
import
establish
latent
infect
matter
cours
interfer
highli
complex
network
human
immun
respons
bear
higher
risk
unforeseen
complic
side
effect
convent
therapi
success
implement
target
immunomodulatori
strategi
requir
detail
knowledg
virusspecif
aspect
pathway
antivir
strategi
discuss
earlier
well
antivir
drug
avail
date
base
principl
convent
chemotherapi
howev
recent
discoveri
develop
molecular
biolog
open
perspect
altern
approach
intervent
import
fraction
novel
approach
involv
target
silenc
viral
gene
express
either
specif
degrad
viral
messeng
rna
block
translat
protein
antisens
rna
ribozym
suggest
evalu
implement
purpos
recent
gene
silenc
mediat
small
interf
rna
sirna
emerg
power
tool
molecular
cell
biolog
although
origin
describ
plant
rna
interfer
also
detect
anim
includ
mammal
find
plant
caenorhabd
elegan
drosophila
indic
may
origin
ancient
intrins
defens
mechan
virus
waterhous
et
al
wilkin
et
al
galianaarnoux
et
al
wang
et
al
sinc
method
gene
silenc
sirna
experiment
set
establish
interf
rna
design
gene
known
sequenc
silenc
virusspecif
gene
rna
interfer
appear
ideal
method
antivir
intervent
principl
see
chapter
haasnoot
berkhout
volum
success
inhibit
viru
replic
tissu
cultur
express
antisens
rna
sirna
demonstr
larg
number
virus
mani
viru
famili
includ
hiv
hcv
hbv
influenza
viru
measl
viru
dengu
viru
sar
coronaviru
ebola
viru
review
see
berkhout
haasnoot
berkhout
first
clinic
trial
evalu
use
sirna
infect
respiratori
synctial
viru
recent
initi
howev
sever
obstacl
overcom
result
translat
applic
sirna
effect
antivir
drug
crucial
point
specif
viral
target
rna
ensur
sirna
intend
use
human
furthermor
method
effici
target
deliveri
therapeut
rna
patient
cell
mainten
antivir
principl
cell
establish
final
method
particularli
sensit
resist
develop
sinc
inhibitori
principl
reli
exact
match
inhibitori
rna
target
rna
sequenc
mutat
target
sequenc
result
viral
escap
inhibit
reason
success
strategi
like
involv
one
target
sequenc
eg
ter
brake
et
al
besid
act
viru
encod
rna
therapeut
rna
also
inhibit
viru
replic
mechan
two
inhibitori
principl
explor
decoy
rna
quench
viral
rna
bind
molecul
mimick
natur
target
site
rna
aptam
review
bunka
stockley
small
rna
select
iter
procedur
high
affin
bind
viral
enzym
structur
protein
interfer
function
besid
regard
potenti
drug
inhibitori
aptam
also
serv
tool
select
small
molecul
compound
compet
aptam
bind
site
differ
kind
antisens
approach
explor
case
hiv
oligodeoxynucleotid
target
polypurin
tract
viral
rna
genom
gener
rnadna
hybrid
prone
destruct
viral
enzym
rnaseh
matzen
et
al
final
virus
also
express
small
rna
mirna
abl
downregul
cellular
mrna
presum
promot
viral
replic
pathogenesi
case
kaposi
sarcoma
associ
herp
viru
one
mirna
shown
function
analog
cellular
mirna
downregul
specif
set
cellular
mrna
gottwein
et
al
target
viral
mirna
antisens
approach
could
therapeut
benefit
target
due
similar
specif
cellular
analog
may
less
prone
resist
mutat
target
deliveri
antivir
rna
molecul
well
gene
encod
antivir
factor
could
accomplish
gene
therapi
see
chapter
von
laer
baum
volum
somat
gene
therapi
introduct
therapeut
effect
gene
within
subset
patient
cell
potenti
ensur
sustain
deliveri
antivir
principl
therebi
allevi
problem
continu
need
medic
chronic
infect
gene
therapeut
approach
could
either
use
select
elimin
infect
cell
render
cell
patient
resist
viru
infect
intracellular
immun
induc
cell
releas
antivir
peptid
environ
complex
less
understood
risk
potenti
gene
therapeut
approach
compar
convent
chemotherapi
gene
therapi
current
consid
otherwis
untreat
potenti
lethal
condit
reason
aid
among
first
diseas
regard
potenti
indic
gene
therapeut
intervent
baltimor
number
potenti
inhibitori
strategi
suggest
evalu
approach
elimin
hiv
infect
cell
overexpress
tcell
receptor
zeta
chain
fusion
protein
autolog
cell
therebi
gener
specif
ctlrespons
cell
express
viral
envelop
protein
unsuccess
mani
strategi
design
intracellular
immun
tcell
hiv
act
number
differ
target
viru
transdomin
version
viral
protein
rna
decoy
ribozym
membranebound
fusion
inhibitor
intracellular
singl
chain
fv
antibodi
fragment
viral
protein
test
vitro
howev
clinic
studi
none
intracellular
immun
strategi
test
far
led
sustain
select
advantag
repopul
immun
system
genet
modifi
tcell
discuss
von
laer
et
al
antivir
resist
short
replic
cycl
may
complet
within
hour
larg
amount
viral
progeni
one
infect
hostcel
well
gener
inaccuraci
viral
nucleic
acid
polymeras
result
evolut
occur
fast
motion
allow
rapid
adapt
virus
select
pressur
see
chapter
boucher
nijhiu
volum
gener
state
effect
antivir
therapi
lead
occurr
resist
mutat
well
studi
exampl
hiv
errorpron
hiv
rt
introduc
averag
mutat
per
nucleotid
per
replic
cycl
manski
temin
mechan
retrovir
replic
favor
genet
recombin
sinc
estim
untreat
hiv
infect
person
new
virion
produc
per
day
ho
et
al
wei
et
al
lead
gener
enorm
number
mutat
viru
variant
mani
random
mutat
incompat
viru
replic
other
minor
effect
respect
consequ
viru
popul
infect
individu
consist
clone
ident
virus
similar
variant
rather
repres
socal
quasispeci
collect
variant
differ
posit
genom
situat
similar
even
wors
hcv
pool
preexist
mutat
also
compris
chanc
confer
degre
resist
antivir
drug
use
therapi
sinc
mutat
often
associ
lower
viral
fit
lower
replic
rate
compar
wildtyp
absenc
drug
gener
repres
minor
fraction
viral
popul
treatment
initi
howev
select
treatment
drug
concentr
insuffici
complet
suppress
replic
moder
resist
viru
replic
drug
select
pressur
result
accumul
adapt
mutat
confer
higher
degre
resist
higher
level
fit
thu
resist
develop
complex
stepwis
process
fig
replic
fit
drug
resist
balanc
respons
environment
condit
mechan
intens
investig
case
hiv
exampl
first
mutat
observ
initi
proteas
inhibitor
treatment
decreas
affin
inhibitor
primari
mutat
sinc
primari
mutat
usual
occur
activ
site
enzym
substrat
bind
catalysi
rate
also
affect
mutat
usual
associ
lower
viral
fit
success
compens
secondari
mutat
outsid
activ
site
increas
resist
level
antivir
therapi
b
c
fig
stepwis
develop
antivir
resist
rapid
mutat
rate
virus
viru
popul
treatment
contain
variant
display
chanc
low
level
resist
drug
indic
darker
hue
treatment
suboptim
level
antivir
drug
b
creat
bottleneck
select
variant
c
replic
presenc
drug
therebi
acquir
addit
mutat
lead
resist
variant
enhanc
replic
fit
restor
replic
capac
case
hiv
pr
tertiari
mutat
outsid
proteas
gene
also
observ
affect
pr
substrat
gag
enhanc
fit
resist
pr
variant
prevent
delay
adapt
cycl
essenti
avoid
suboptim
drug
treatment
regimen
resist
develop
occur
extrem
rapid
illustr
experi
use
singl
dose
nevirapin
singl
peripartum
dose
nevirapin
effici
reduc
rate
mothertochildtransmiss
hiv
therefor
part
mani
regimen
hivinfect
pregnant
women
without
access
antivir
therapi
howev
case
nevirapin
singl
point
mutat
rt
alreadi
confer
high
resist
pharmacokinet
properti
drug
result
suboptim
level
sustain
organ
day
sever
studi
reveal
nevirapin
resist
viru
variant
detect
blood
sampl
mother
infect
infant
follow
singl
dose
exposur
jackson
et
al
eshleman
et
al
eshleman
et
al
lee
et
al
fli
et
al
shapiro
et
al
although
detail
data
avail
hiv
resist
problem
cours
limit
viru
observ
potent
antivir
cours
treatment
chronic
hepat
b
lamivudin
resist
viru
variant
emerg
rapidli
rate
increas
time
culmin
therapi
resist
viru
approxim
patient
year
treatment
lok
et
al
crossresist
sever
inhibitor
one
class
multiresist
one
class
drug
also
observ
furthermor
resist
viru
variant
transmit
reason
resist
develop
sever
limit
use
antivir
drug
exampl
sequenc
influenza
viru
isol
circul
usa
begin
season
reveal
isol
carri
mutat
correl
amantadin
resist
conclud
drug
present
use
treatment
prophylaxi
influenza
countri
bright
et
al
similarli
surveil
hiv
drug
resist
europ
show
viru
variant
resist
one
antiretrovir
drug
detect
patient
wens
et
al
exampl
illustr
increas
avail
use
antivir
drug
problem
resist
develop
rapidli
increas
point
diminish
limit
arsen
drug
avail
antivir
treatment
resist
monitor
becom
increasingli
import
part
antivir
drug
treatment
regimen
molecular
mechan
underli
resist
well
evolut
monitor
prevent
antivir
resist
thu
continu
topic
central
signific
field
antivir
research
virus
import
human
pathogen
caus
tremend
burden
diseas
death
worldwid
thu
antivir
drug
urgent
requir
although
viru
replic
reli
larg
host
factor
therefor
difficult
target
develop
potent
specif
antivir
import
pathogen
virus
particular
hiv
herp
virus
hsv
cmv
hbv
influenza
viru
accomplish
build
experi
consider
expans
antivir
arsen
expect
futur
howev
increas
therapeut
option
increas
access
antivir
drug
inevit
connect
increas
resist
develop
turn
creat
constant
need
care
monitor
resist
develop
altern
antivir
drug
new
pathogen
virus
continu
emerg
creat
need
novel
virostat
thu
antivir
drug
develop
repres
field
grow
import
year
come
classic
pharmacotherapi
small
molecul
chemic
direct
virusspecif
function
like
continu
major
forc
antivir
therapi
increasingli
complement
approach
promis
altern
approach
drug
affect
nonessenti
host
factor
involv
viru
replic
virusspecif
modif
factor
well
sirna
direct
viral
cellular
gene
strategi
target
cellular
factor
well
novel
immunomodulatori
therapi
may
hold
potenti
defin
drug
effect
one
class
virus
truli
broadspectrum
antivir
